H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of $107, up from $90, after Merck said it will acquire Verona for $107 per American depository share. The firm does not expect any competitors to attempt to outbid Merck.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Overweight at Piper Sandler
- Verona Pharma downgraded to Hold from Buy at Truist
- Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal